Abstract: Chen Sheng′an, Yang Fanping, Xue Haiyu, Luo Xiaoqun Department of Dermatology, Huashan Hospital, Fudan University, Shanghai 200040, China Corresponding author: Luo Xiaoqun, Email: luoxiaoqun913@163.com 【Abstract】 Objective To compare clinical and laboratory characteristics between systemic lupus erythematosus （SLE） patients with and without cutaneous vasculitis, and to investigate the correlation of cutaneous vasculitis with severe visceral involvement and laboratory biomarkers. Methods A total of 152 SLE patients with various skin manifestations were enrolled from Department of Dermatology of Huashan Hospital affiliated to Fudan University from July 2011 to October 2014. The clinical and laboratory data were collected and retrospectively analyzed. SLE patients with cutaneous vasculitis were divided into upper/lower extremity vasculitis group and livedo reticularis group. A logistic regression model was used to analyze the correlation between cutaneous vasculitis and various clinical and laboratory variables. Results Of 152 SLE patients, 62 （41%） presented with cutaneous vasculitis, including 55 with upper/lower extremity vasculitis and 7 with livedo reticularis, and 90 （59%） did not have cutaneous vasculitis. Patients with upper/lower extremity vasculitis showed significantly younger age （30.54 ± 12.67 years vs. 37.77 ± 12.17 years）, and lower prevalence of aberrantly elevated 24?hour protein excretion （39.39% vs. 64.00%） and serum urea level （2.08% vs. 16.43%）, but significantly higher percentage of females （98.18% vs. 84.44%）, higher proportions of patients with abnormal brain MRI （37.5% vs. 12.19% ）, anemia （87.03% vs. 70.93%） and positive anti?ribosomal P protein antibodies （77.77% vs. 53.65%）, and higher SLE disease activity index （SLEDAI） （14.71 ± 7.75 vs. 10.68 ± 5.61） than those without vasculitis （all P < 0.05 ）. The proportion of patients with decreased C3 level did not differ between patients with upper/lower extremity vasculitis and those without cutaneous vasculitis （P = 0.362）, but was significantly lower in the patients with livedo reticularis than in those without cutaneous vasculitis （28.57% vs. 79.76%, P = 0.008）. However, no significant differences in the other variables were observed between patients with livedo reticularis and those without cutaneous vasculitis （all P > 0.05）. Additionally, body mass index （BMI）, abnormal lung function and other laboratory variables all did not differ among patients with upper/lower extremity vasculitis, patients with livedo reticularis and patients without cutaneous vasculitis （all P > 0.05）. Logistic regression analysis revealed that after exclusion of potential effects of age and gender, cutaneous vasculitis was significantly positively correlated with abnormal brain MRI （OR = 4.24, 95% CI: 1.17 - 16.13, P = 0.028）, and positive anti?ribosomal P protein antibodies （OR = 3.97, 95% CI: 1.86 - 8.47, P = 0.0004）, but negatively correlated with abnormally elevated 24?hour protein excretion （OR = 0.25, 95% CI: 0.09 - 0.69, P = 0.009）. Furthermore, cutaneous vasculitis showed no significant associations with abnormal serum urea level （OR = 0.12, 95% CI: 0.01 - 1.06）, decreased C3 level （OR = 0.93, 95% CI: 0.38 - 2.28）, anemia （OR = 1.38, 95% CI: 0.56 - 3.40） or SLEDAI （OR = 1.05, 95% CI: 0.98 - 1.14）. Conclusions Cutaneous vasculitis is closely associated with central nervous system damage and emergence of anti?ribosomal P protein antibodies, so SLE patients with cutaneous vasculitis should be closely monitored for central nervous system damage. SLE patients without cutaneous vasculitis are more liable to kidney injury, so they also need to be closely monitored.